TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9072602

Group type: EXPERIMENTAL
Intervention: 280 mg estramustine phosphate 2 times daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 8174837

Group type: EXPERIMENTAL
Intervention: Mental stress (evoked by a modified filmed version of Stroop's CWT for 20 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (resting quietly for 20 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 10
Study: 2906888

Group type: COMPARATOR
Intervention: SASP (1 g, n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SAB (0.72 g, n = 22)
Number of subjects: 43
Study: 2044398

Group type: EXPERIMENTAL
Intervention: 200 mg naftidrofuryl twice daily in slow-release form
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 947143

Group type: EXPERIMENTAL
Intervention: Low-lactose skim milk
Number of subjects: 12

Group type: COMPARATOR
Intervention: Skim milk
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lactose (12.5 gm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose plus galactose (6 gm each)
Number of subjects: 12
Study: 31165457

Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg·kg−1)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Neostigmine (40 µg)
Number of subjects: 130
Study: 27771984

Group type: EXPERIMENTAL
Intervention: Desflurane inhalation anesthesia (Group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol total intravenous anesthesia with ischemic preconditioning (Group TIP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol total intravenous anesthesia (Group T)
Number of subjects: 100
Study: 26009577

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) plus standard therapy of intravenous methylprednisolone (IVMP)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard therapy of intravenous methylprednisolone (IVMP)
Number of subjects: 170
Study: 23997695

Group type: EXPERIMENTAL
Intervention: Positive airway pressure treatment for ≥ 2 months
Number of subjects: 20
Study: 21710417

Group type: EXPERIMENTAL
Intervention: Modified case-based reasoning seminars
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard case-based reasoning seminars (control)
Number of subjects: 29
Study: 19538239

Group type: EXPERIMENTAL
Intervention: Ubiquitous Chronic Disease Care (UCDC) system using cellular phones and the internet
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 16620355

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin lispro (0.075 U/kg/hour after a bolus of 0.15 U/kg IV regular insulin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous regular insulin (bolus of 0.15 U/kg followed by infusion)
Number of subjects: 20
Study: 15282386

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Air (Control)
Number of subjects: 18
Study: 11289469

Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 244

Group type: COMPARATOR
Intervention: FPG measurement
Number of subjects: 244
Study: 9226738

Group type: COMPARATOR
Intervention: 20 micrograms/kg nicotine by nasal spray
Number of subjects: 21

Group type: COMPARATOR
Intervention: 20 micrograms/kg nicotine
Number of subjects: 21

Group type: COMPARATOR
Intervention: 12 micrograms/kg nicotine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subjective measure of 'head rush'
Number of subjects: 21

Group type: COMPARATOR
Intervention: Self-administration of nicotine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Self-administration behavior
Number of subjects: 21

Group type: COMPARATOR
Intervention: Generalization doses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Confidence in discriminating training doses
Number of subjects: 21
Study: 7944440

Group type: EXPERIMENTAL
Intervention: Continuous arterial infusion group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose arterial infusion group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Repeated one-shot arterial infusion group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose arterial infusion of 5-FU
Number of subjects: 51
Study: 3146989

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 56

Group type: COMPARATOR
Intervention: Digoxin and disopyramide
Number of subjects: 56
Study: 29278870

Group type: EXPERIMENTAL
Intervention: Stabilization exercises including motor control training (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Strengthening exercises for back muscles, abdominal muscles, and hip muscles (Control group, n=10)
Number of subjects: 21
Study: 28877510

Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 10
Study: 24771228

Group type: EXPERIMENTAL
Intervention: Vital pulp therapy using calcium-enriched mixture cement (VPT/CEM)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 407
Study: 23153963

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400mg daily intravenous for 5-14 days)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Ertapenem (1g daily intravenous for 5-14 days)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 699

Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 699
Study: 21714645

Group type: EXPERIMENTAL
Intervention: Insulin lispro with 5 μg/mL rHuPH20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular insulin with 5 μg/mL rHuPH20
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 0
Study: 19418937

Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 16896576

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 63
Study: 16281587

Group type: EXPERIMENTAL
Intervention: 15% azelaic acid gel
Number of subjects: 580

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide (BPO)
Number of subjects: 580

Group type: COMPARATOR
Intervention: 1% clindamycin
Number of subjects: 580
Study: 11561268

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: No clonidine (Control)
Number of subjects: 46
Study: 9598255

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone (5 mg.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone plus Atracurium (5 mg.kg‐1 thiopentone plus 0.05 mg.kg‐1 atracurium)
Number of subjects: 60
Study: 7945786

Group type: EXPERIMENTAL
Intervention: Balsam of Peru (225 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Natural vanilla (50 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Artificial vanillin (12.5 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Eviction of food flavouring agents
Number of subjects: 11
Study: 3345963

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral coping skills training in a group setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 31492147

Group type: EXPERIMENTAL
Intervention: Contraceptive Use Stigma (CUS) scale
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Adolescents Stigmatizing Attitudes, Beliefs and Action (ASABA) scale
Number of subjects: 633
Study: 28235882

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA) at a dose of 2 mg/kg every 3 weeks by intravenous infusion
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA)
Number of subjects: 89
Study: 25352527

Group type: EXPERIMENTAL
Intervention: keepin' it REAL program (implemented in 7th grade)
Number of subjects: 581

Group type: COMPARATOR
Intervention: treatment-as-usual condition
Number of subjects: 581
Study: 23944211

Group type: EXPERIMENTAL
Intervention: Protocolised care (using minimally invasive haemodynamic monitoring)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21765074

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Amphotericin B followed by fluconazole
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no ocular involvement)
Number of subjects: 370
Study: 19687393

Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-frequency treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electrocautery treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Partial inferior turbinotomy
Number of subjects: 80
Study: 16506681

Group type: EXPERIMENTAL
Intervention: Nebulised lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 14716702

Group type: EXPERIMENTAL
Intervention: Telephone Interview for Cognitive Status (TICS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Modified Telephone Interview for Cognitive Status (TICSm)
Number of subjects: 64

Group type: COMPARATOR
Intervention: R-CAMCOG
Number of subjects: 64
Study: 11075313

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg once daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15321290

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with intermittent injection through the epidural needle
Number of subjects: 88

Group type: COMPARATOR
Intervention: Epidural anesthesia via a previously placed catheter
Number of subjects: 88
Study: 1396287

Group type: EXPERIMENTAL
Intervention: Osterprem
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prematil
Number of subjects: 30
Study: 3929127

Group type: EXPERIMENTAL
Intervention: Personalized Nursing Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Personalized Nursing Intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Personalized Nursing Intervention with network participation
Number of subjects: 0
Study: 31397413

Group type: EXPERIMENTAL
Intervention: Passive self-ligating system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional appliances
Number of subjects: 60
Study: 30589029

Group type: EXPERIMENTAL
Intervention: Group D + S (Dexmedetomidine + Sevoflurane)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group M + S (Sevoflurane)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group M + P (Control group with no dexmedetomidine)
Number of subjects: 120
Study: 25011935

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment
Number of subjects: 744
Study: 23411674

Group type: EXPERIMENTAL
Intervention: Specific interaction causing the sound (e.g. trickling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: More general descriptions (e.g. pour, liquid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: More detailed descriptions using adverbs (e.g. trickling evenly)
Number of subjects: 0
Study: 21477273

Group type: EXPERIMENTAL
Intervention: Community-based mentoring service
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (matched participants from general practice)
Number of subjects: 195
Study: 20016179

Group type: EXPERIMENTAL
Intervention: Intensive fluoride 5% sodium varnish regimen (three applications/2 weeks)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard semiannual application of fluoride varnish (one active and two placebo treatments every 6 months)
Number of subjects: 600
Study: 18085143

Group type: EXPERIMENTAL
Intervention: Acupuncture at point 'Xiajiquan' plus standard acupoints (Quchi, Shousanli, Waiguan)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard acupuncture at Quchi (LI 11), Shousanli (LI 10), Waiguan (TE 5)
Number of subjects: 123
Study: 15200736

Group type: EXPERIMENTAL
Intervention: New formulation of sumatriptan 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: New formulation of sumatriptan 100 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional sumatriptan tablets
Number of subjects: 32
Study: 11575388

Group type: EXPERIMENTAL
Intervention: Combitube (37Fr) small adult
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 40
Study: 9835439

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo + Salbutamol
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo + Beclomethasone
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Beclomethasone + Salbutamol
Number of subjects: 173
Study: 9776856

Group type: EXPERIMENTAL
Intervention: Conditioned media from non-insulin-dependent diabetes mellitus wound fibroblasts
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Addition of 6 mmol/L l-lactate to uninjured normal fibroblasts
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increasing d-glucose in the media
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Treatment with beta-hydroxybutyrate on uninjured normal cells
Number of subjects: 2
Study: 1652976

Group type: EXPERIMENTAL
Intervention: Sequential use of Tamoxifen, Premarin, and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHRH agonists and tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-OHA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toremifene and RU486
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New hormonal agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of chemotherapy and hormonal therapy
Number of subjects: 0
Study: 6684029

Group type: EXPERIMENTAL
Intervention: Continuous protocol (C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Discontinuous protocol (D)
Number of subjects: 20
Study: 30781525

Group type: EXPERIMENTAL
Intervention: Motivational intervention group
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 334
Study: 31105911

Group type: EXPERIMENTAL
Intervention: Guided Self-Change (GSC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combined GSC-NRT
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 57
Study: 26630949

Group type: EXPERIMENTAL
Intervention: CAM nursing package, resource-oriented counseling, evidence-based information material on CAM
Number of subjects: 0
Study: 24423336

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 22172901

Group type: EXPERIMENTAL
Intervention: High-dose adjuvant radiotherapy (HD-ART) with androgen deprivation therapy (ADT)
Number of subjects: 225

Group type: COMPARATOR
Intervention: High-dose adjuvant radiotherapy (HD-ART) without androgen deprivation therapy (ADT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy at the time of RP
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: High-dose adjuvant radiotherapy (HD-ART)
Number of subjects: 225
Study: 20483660

Group type: EXPERIMENTAL
Intervention: Ramelteon 1 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 18760136

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice a day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 16137513

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 12416358

Group type: EXPERIMENTAL
Intervention: Cimetidine, 25 to 30 mg/kg daily for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 60
Study: 9809089

Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spontaneous assisted ventilation (SAV)
Number of subjects: 38
Study: 8062954

Group type: EXPERIMENTAL
Intervention: Triptorelin [INN]
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Buserelin acetate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and hMG
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 150
Study: 3055874

Group type: EXPERIMENTAL
Intervention: 10 mg mifentidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 mg mifentidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29529919

Group type: EXPERIMENTAL
Intervention: Kinect-based VR training + Physical Therapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical Therapy (PT) only
Number of subjects: 0
Study: 28266243

Group type: EXPERIMENTAL
Intervention: PASI 90-100 responders at week 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PASI 90-100 responders at week 52
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IGA ratings of Clear or Almost Clear
Number of subjects: 0

Group type: COMPARATOR
Intervention: PASI 75-89 responders
Number of subjects: 0
Study: 25333885

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 151
Study: 23540216

Group type: EXPERIMENTAL
Intervention: RehaCom rehabilitation programme
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no RehaCom training)
Number of subjects: 81
Study: 21174253

Group type: EXPERIMENTAL
Intervention: Playing Dr. Kawashima's Brain Training on a Nintendo DS handheld console for 10 days post-surgery.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no video games).
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 32
Study: 18811813

Group type: EXPERIMENTAL
Intervention: Magnetic navigation (Niobe system and Helios II catheter)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Manual navigation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Magnetic navigation
Number of subjects: 71
Study: 16896731

Group type: EXPERIMENTAL
Intervention: Equitation training for 14 weeks, 5 days/week
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 12672309

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg daily for adults, 200 microg for children younger than 11 years)
Number of subjects: 7241

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7241
Study: 11091231

Group type: EXPERIMENTAL
Intervention: QUOROM statement checklist
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: QUOROM statement flow diagram
Number of subjects: 30
Study: 8675160

Group type: EXPERIMENTAL
Intervention: [(13)C 3‐methyl] caffeine breath test (CBT) administered to 20 patients at a dosage of 2 mg/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Commercially available CBT kit with a constant 200-mg dose administered to 17 patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Standardized-dose CBT
Number of subjects: 37
Study: 1562332

Group type: EXPERIMENTAL
Intervention: Benzonatate 200 mg topically for oropharyngeal anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bilateral superior laryngeal nerve blocks (total 8 ml of 1% lidocaine) and 2 ml of 20% benzocaine orally
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups administered 4 ml of 4% lidocaine translaryngeally
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2866725

Group type: EXPERIMENTAL
Intervention: Levocabastine (topical eye drops)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (topical eye drops)
Number of subjects: 40
Study: 30219436

Group type: EXPERIMENTAL
Intervention: Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebos of Ginkgo Leaf Tablets and Liuwei Dihuang Pills
Number of subjects: 140
Study: 26059745

Group type: EXPERIMENTAL
Intervention: Combination of extracts from grape seed and skin (330 mg), green tea (100 mg), resveratrol (60 mg), quercetin, ginkgo biloba and bilberry (60 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of extracts from grape seed and skin, green tea, resveratrol, quercetin, ginkgo biloba and bilberry
Number of subjects: 18
Study: 25371542

Group type: EXPERIMENTAL
Intervention: Culprit-vessel intervention (CVI)
Number of subjects: 3984
Study: 23059776

Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed 500 mg/m plus best supportive care
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 20662624

Group type: EXPERIMENTAL
Intervention: CYP2B6 516/983 genotype
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Slow‐metabolizer genotypes
Number of subjects: 821
Study: 18703166

Group type: EXPERIMENTAL
Intervention: Comprehensive outpatient educational intervention
Number of subjects: 0
Study: 15968496

Group type: EXPERIMENTAL
Intervention: Mammograms highly suggestive of malignancy (category 5)
Number of subjects: 7670

Group type: EXPERIMENTAL
Intervention: Suspicious mammograms (category 4)
Number of subjects: 7670

Group type: EXPERIMENTAL
Intervention: Other mammography assessments (categories 0-3)
Number of subjects: 7670

Group type: EXPERIMENTAL
Intervention: Presence of a lump, absence of mammogram calcifications
Number of subjects: 7670
Study: 11967719

Group type: EXPERIMENTAL
Intervention: Low salt intake (20 mmol/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Furosemide administration (40 mg/8 h orally)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous saline load (2 litres over 4 hours) followed by low salt intake (20 mmol) and furosemide administration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dietary salt intake (high 260 mmol/day)
Number of subjects: 29